Tekmira Pharmaceuticals, the Vancouver, BC-based developer of technology to RNA interference drugs, said today it has signed a four-year collaboration with Bristol-Myers Squibb. Bristol will pay Tekmira $3 million upfront, while Tekmira will be asked to deliver a pre-determined number of batches of RNAi drug candidates in lipid nanoparticles. Tekmira has other collaborations with Pfizer, Roche, and Alnylam Pharmaceuticals.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
